A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.
What Are The Drugs Involved
The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.
The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.
These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.
What Could This Mean For Bowel Cancer Treatment In The Future
The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.
All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.
Credits: Canva
DengiAll, India's first indigenous dengue vaccination, has completed its Phase-III human trials across 19 locations in India and is now waiting for final approval before being distributed across the country.
The vaccine, which has been in development since 2008 and is set to hit shelves in 2027, is a single dose medication that protects patients from all four variants of dengue fever.
Made by Panacea Biotec with technology from the US National Institutes of Health (NIH), the vaccine aims to provide long-term immunity and reduce the significant public health burden of dengue fever in India and globally.
Dr Syed Khalid Ali, Chief Scientific Officer at Panacea Biotec told The Print, "Dengue has puzzled scientists and immunologists for decades now. People infected with it can show anything from mild flu-like symptoms to even death. A lot of it has to do with the serotypes of dengue, and how they interact with each other.
"DengiAll has been in the making for over 15 years, and it comes at a time when half the world’s population is at risk of dengue. There’s no question about need. We needed such a vaccine yesterday.”
DengiAll works by using live, weakened versions of all four dengue virus types (DEN1, DEN2, DEN3 and DEN4) in a single shot to train the immune system to recognize and fight all variants of the virus and and protect the body from future natural infections.
The vaccine is also a tetravalent vaccine meaning that it is designed to provide balanced immunity against all four variants and overcome the challenge of each of the different types, making it a crucial feature as getting a second dengue infection with a different serotype can be more severe and deadly.
Dr Ali explains, "The catch is, if you get infected with one serotype, you’re only protected from that one type. You can very likely get infected with dengue again, with another serotype. In fact, the second infection is more likely to be severe, even life-threatening."
Transmitted by Aedes mosquitoes, dengue presents with high fever, headache, joint pain and rash, and while often severe forms can be fatal. Over the years,
the mosquito-borne disease has become a major public health concern in India, ranking among the top 30 countries with the highest incidence of the disease.
States such as Karnataka, Tamil Nadu, and Maharashtra often report high case numbers annually after monsoons due to climate change, urbanization, and multiple virus strains. According to Global HealthCare Academy, around 1.5 to 2 lakh people fall sick from it every year.
The global incidence of dengue has been steadily increasing over the past two decades, with more than 129 countries reporting dengue viral disease by the end of 2023, according to the World Health Organization.
Apart from DengiAll, Butantan-DV is the only other single-dose, live-attenuated dengue vaccine approved in Brazil for ages 12-59 and is expected to rollout in 2026.
Credits: iStock
AIIMS New Delhi launched free cervical cancer screening through January as a public interest drive. In India, in every 8 minutes, 1 woman loses her life to cervical cancer, however, doctors say that it is highly preventable. Thus, as part of the Cervical Cancer Awareness Month, Preventative Oncology at the Institute of Rotary Cancer Hospital and the National Cancer Institute, in collaboration with the College of Nursing, is offering the WHO-recommended HPV testing, follow-up care, and vaccination.
Dr Pallavi Shukla, Associate Professor of Preventative Oncology, AIIMS, who is coordinating the programme said, "This is one cancer which is absolutely preventable. Women should not neglect their health at any age, we must make earnest efforts to eliminate cervical cancer from India."
Also Read: Every Two Minutes, One Woman Loses Her Life To Cervical Cancer: UN
Cervical Cancer is a type of cancer that develops in layers of the cervix. It is caused by abnormal cell growth that can spread to another part of your body. There are two main types of cervical cancer. These are squamous cell carcinoma and adenocarcinoma.
Cervix is located in the pelvic cavity, about 3 to 6 inches inside the vaginal canal. It serves as the entrance to the uterus to the vagina. As per the World Health Organization (WHO), almost all cervial cancer are linked to human papillomaviruses (HPV) which are transmitted through sexual contact.
Cervical cancer has no symptoms in the early days and therefore, is hard to detect until it has spread.
Cervical cancer is largely preventable and, when detected early, highly treatable. The World Health Organization recommends HPV vaccination for girls aged 9 to 14, before they become sexually active, along with regular cervical screening from age 30, or 25 for women living with HIV.
Despite this, unequal access to vaccination, screening and treatment continues to drive higher rates of illness and deaths in regions such as sub-Saharan Africa, Central America and Southeast Asia.
Credits: iStock
Pilot project to provide menstrual cups to school and college students in selected districts of Karnataka has been successfully implemented and now the Department of Health and Family Welfare has decided to expand the scheme across the state. The Government order noted a revised administrative approval which granted to provide 10,38,912 menstrual cups at a cost of more than Rs 61 crores through Karnataka State Medical Supplies Corporation Limited (KSMSCL) under the Swachh Bharat Abhiyan.
This decision is said to cut government expenditure on sanitary napkins by Rs 10 crores. The government spend Rs 71 crores to purchase 2,35,74,084 sanitary napkins annually to provide to beneficiaries of the Shuchi scheme. The revised order states that the department will continue distributing sanitary napkins for the next three months, after which students will be provided one menstrual cup for the following academic year.
Menstrual cups are a small, reusable intimate product used to collect period blood. It is not only good for maintaining menstrual hygiene but is also good for the environment.
Learning to use a menstrual cup properly might take some time and practice. If you have questions about which cup to choose or how to use it, your gynecologist can provide guidance. It's common to have some difficulty during the first few uses, but most people become comfortable by their third menstrual cycle. Here is how you insert it for use:
The problem arose because the menstrual cup wasn't sitting where it is supposed to be. The cup was pressing on the tube that carries urine from the kidney to the bladder, essentially blocking the flow. This blockage led to pain and other symptoms for the woman. While this is a very rare occurrence, it emphasizes the importance of understanding how the cup interacts with your body.
Lancet health explains that a poorly fitted menstrual cup can cause issues like leakage from improper fit or fullness, pain or minor injuries from insertion, rare allergic reactions, and possible urinary problems due to urethral irritation or blockage. Though infrequent, IUD dislodgement has been reported, but it's difficult to definitively link it to cup use. Infections, including the very rare toxic shock syndrome (TSS), are possible if cups aren't properly cleaned, but studies suggest they may be less risky than tampons or pads. Overall, while complications are possible, they are generally infrequent.
The size of the cup, how it's placed, how long it's used, and each person's unique body shape all play a role. Even though this kind of complication is unlikely with regular use, it's a good reminder to pay attention to how you use menstrual cups and to be aware of potential issues.
The size of the cup, how it's placed, how long it's used, and each person's unique body shape all play a role. Even though this kind of complication is unlikely with regular use, it's a good reminder to pay attention to how you use menstrual cups and to be aware of potential issues.
© 2024 Bennett, Coleman & Company Limited